Financial ResourcesCash, cash equivalents, and investments totaled $78.5M, anticipated to fund operations into 2028.
Market OpportunityAN2 continues to expect to unblind its Phase 3 for refractory MAC NTM next quarter, which could point to a >$1B opportunity.
Pipeline DevelopmentANTX plans to use non-dilutive funding to help advance epetraborole for the treatment of non-tuberculous mycobacterial (NTM) lung disease caused by M. abscessus.